Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability

Area of Science:

• Oncology
• Molecular Biology
• Canine Cancer Research

Background:

• Isocitrate dehydrogenase 1 (IDH1) mutations, particularly R132H, are prevalent in various cancers, including gliomas and chondrosarcoma.
• The R132H mutation produces the carcinogen 2-hydroxyglutarate (2-HG) and elevates hypoxia-inducible factor-1α (HIF-1α), promoting carcinogenesis.
• Similar IDH1 R132 mutations have been observed in canine tumors.

Purpose of the Study:

• To identify and characterize novel mutations in canine IDH1 (cIDH1) associated with chondrosarcoma.
• To investigate the functional consequences of a newly discovered Tyr208Cys (Y208C) mutation in cIDH1.
• To elucidate the potential mechanisms by which Y208C contributes to tumorigenesis in dogs.

Main Methods:

• Genomic DNA isolation and sequencing from canine chondrosarcoma tissues and blood.
• Biochemical assays to assess isocitrate dehydrogenase activity of mutant cIDH1.
• Cell-based assays to evaluate HIF-1α pathway activation.
• In silico and cell biological analyses of IDH1 dimerization.

Main Results:

• A novel somatic mutation, Tyr208Cys (Y208C), was identified in 2 of 45 canine chondrosarcoma cases.
• Y208C mutant cIDH1 showed attenuated enzymatic activity, less severe than the R132H mutation.
• Y208C overexpression did not increase HIF-1α activity; however, it attenuated binding with wild-type cIDH1, unlike R132H.

Conclusions:

• The Y208C mutation in cIDH1 represents a novel mechanism of tumorigenesis in canine chondrosarcoma.
• Unlike the R132H mutation's pathway involving 2-HG and HIF-1α, Y208C appears to promote cancer by disrupting IDH1 dimerization.
• This discovery highlights distinct molecular pathways in IDH1-driven cancers and offers insights into canine tumor biology.